Comparative in vitro activity of thiamphenicol-glycinate and thiamphenicol-glycinate-acetylcysteinate and other antimicrobials against respiratory pathogens

L. Drago, E. De Vecchi, M. C. Fassina, B. Mombelli, L. Tocalli, M. R. Gismondo

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Thiamphenicol-glycinate-acetylcysteinate (TGA; CAS 20192-91-0) is widely used for the treatment of infections of varied aetiology. The aim of this study was to compare the antibacterial activity of thiamphenicol-glycinate (TG; CAS 15318-45-3), TGA, amoxicillin (CAS 61336-70-7) plus clavulanic acid (CAS 58001-44-8), azithromycin (CAS 83905-01-5) and ceftriaxone (CAS 104376-79-6). Minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) were determined against Staphylococcus aureus, Klebsiella pneumoniae, Streptococcus pyogenes, Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae according to the National Committee for Clinical Laboratory Standards (NCCLS) methods. The effects of changes in assay conditions were also examined. The activity of TG and TGA was similar to that of amoxicillin plus clavulanic acid, with the exception of methicillin resistant S. aureus. Azithromycin and ceftriaxone were characterised by a limited activity against gram-positive cocci and methicillin resistant and cefinasepositive S. aureus, respectively. TG and TGA are characterized by a wide spectrum of activity, comparable to that of recent commercialized antibiotics for treatment of respiratory tract infections.

Original languageEnglish
Pages (from-to)315-324
Number of pages10
JournalArzneimittel-Forschung/Drug Research
Volume51
Issue number4
Publication statusPublished - 2001

Fingerprint

Clavulanic Acid
Azithromycin
Methicillin
Ceftriaxone
Amoxicillin
Pathogens
Clinical laboratories
Methicillin-Resistant Staphylococcus aureus
Staphylococcal Pneumonia
Moraxella (Branhamella) catarrhalis
Amoxicillin-Potassium Clavulanate Combination
Gram-Positive Cocci
Assays
Streptococcus pyogenes
Haemophilus influenzae
Klebsiella pneumoniae
Microbial Sensitivity Tests
Anti-Bacterial Agents
Streptococcus pneumoniae
Respiratory Tract Infections

Keywords

  • Amoxicillin plus clavulanic acid
  • Antimicrobials
  • Azithromycin
  • Ceftriaxone
  • Clavulanic acid
  • Thiamphenicol-glycinate
  • Thiamphenicol-glycinate-acetylcysteinate

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Chemistry(all)
  • Pharmacology

Cite this

Comparative in vitro activity of thiamphenicol-glycinate and thiamphenicol-glycinate-acetylcysteinate and other antimicrobials against respiratory pathogens. / Drago, L.; De Vecchi, E.; Fassina, M. C.; Mombelli, B.; Tocalli, L.; Gismondo, M. R.

In: Arzneimittel-Forschung/Drug Research, Vol. 51, No. 4, 2001, p. 315-324.

Research output: Contribution to journalArticle

@article{10d5f1d00fac42dda3890244a56a29a7,
title = "Comparative in vitro activity of thiamphenicol-glycinate and thiamphenicol-glycinate-acetylcysteinate and other antimicrobials against respiratory pathogens",
abstract = "Thiamphenicol-glycinate-acetylcysteinate (TGA; CAS 20192-91-0) is widely used for the treatment of infections of varied aetiology. The aim of this study was to compare the antibacterial activity of thiamphenicol-glycinate (TG; CAS 15318-45-3), TGA, amoxicillin (CAS 61336-70-7) plus clavulanic acid (CAS 58001-44-8), azithromycin (CAS 83905-01-5) and ceftriaxone (CAS 104376-79-6). Minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) were determined against Staphylococcus aureus, Klebsiella pneumoniae, Streptococcus pyogenes, Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae according to the National Committee for Clinical Laboratory Standards (NCCLS) methods. The effects of changes in assay conditions were also examined. The activity of TG and TGA was similar to that of amoxicillin plus clavulanic acid, with the exception of methicillin resistant S. aureus. Azithromycin and ceftriaxone were characterised by a limited activity against gram-positive cocci and methicillin resistant and cefinasepositive S. aureus, respectively. TG and TGA are characterized by a wide spectrum of activity, comparable to that of recent commercialized antibiotics for treatment of respiratory tract infections.",
keywords = "Amoxicillin plus clavulanic acid, Antimicrobials, Azithromycin, Ceftriaxone, Clavulanic acid, Thiamphenicol-glycinate, Thiamphenicol-glycinate-acetylcysteinate",
author = "L. Drago and {De Vecchi}, E. and Fassina, {M. C.} and B. Mombelli and L. Tocalli and Gismondo, {M. R.}",
year = "2001",
language = "English",
volume = "51",
pages = "315--324",
journal = "Arzneimittel-Forschung/Drug Research",
issn = "0004-4172",
publisher = "Editio Cantor Verlag GmbH",
number = "4",

}

TY - JOUR

T1 - Comparative in vitro activity of thiamphenicol-glycinate and thiamphenicol-glycinate-acetylcysteinate and other antimicrobials against respiratory pathogens

AU - Drago, L.

AU - De Vecchi, E.

AU - Fassina, M. C.

AU - Mombelli, B.

AU - Tocalli, L.

AU - Gismondo, M. R.

PY - 2001

Y1 - 2001

N2 - Thiamphenicol-glycinate-acetylcysteinate (TGA; CAS 20192-91-0) is widely used for the treatment of infections of varied aetiology. The aim of this study was to compare the antibacterial activity of thiamphenicol-glycinate (TG; CAS 15318-45-3), TGA, amoxicillin (CAS 61336-70-7) plus clavulanic acid (CAS 58001-44-8), azithromycin (CAS 83905-01-5) and ceftriaxone (CAS 104376-79-6). Minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) were determined against Staphylococcus aureus, Klebsiella pneumoniae, Streptococcus pyogenes, Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae according to the National Committee for Clinical Laboratory Standards (NCCLS) methods. The effects of changes in assay conditions were also examined. The activity of TG and TGA was similar to that of amoxicillin plus clavulanic acid, with the exception of methicillin resistant S. aureus. Azithromycin and ceftriaxone were characterised by a limited activity against gram-positive cocci and methicillin resistant and cefinasepositive S. aureus, respectively. TG and TGA are characterized by a wide spectrum of activity, comparable to that of recent commercialized antibiotics for treatment of respiratory tract infections.

AB - Thiamphenicol-glycinate-acetylcysteinate (TGA; CAS 20192-91-0) is widely used for the treatment of infections of varied aetiology. The aim of this study was to compare the antibacterial activity of thiamphenicol-glycinate (TG; CAS 15318-45-3), TGA, amoxicillin (CAS 61336-70-7) plus clavulanic acid (CAS 58001-44-8), azithromycin (CAS 83905-01-5) and ceftriaxone (CAS 104376-79-6). Minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) were determined against Staphylococcus aureus, Klebsiella pneumoniae, Streptococcus pyogenes, Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae according to the National Committee for Clinical Laboratory Standards (NCCLS) methods. The effects of changes in assay conditions were also examined. The activity of TG and TGA was similar to that of amoxicillin plus clavulanic acid, with the exception of methicillin resistant S. aureus. Azithromycin and ceftriaxone were characterised by a limited activity against gram-positive cocci and methicillin resistant and cefinasepositive S. aureus, respectively. TG and TGA are characterized by a wide spectrum of activity, comparable to that of recent commercialized antibiotics for treatment of respiratory tract infections.

KW - Amoxicillin plus clavulanic acid

KW - Antimicrobials

KW - Azithromycin

KW - Ceftriaxone

KW - Clavulanic acid

KW - Thiamphenicol-glycinate

KW - Thiamphenicol-glycinate-acetylcysteinate

UR - http://www.scopus.com/inward/record.url?scp=0035035756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035035756&partnerID=8YFLogxK

M3 - Article

C2 - 11367873

AN - SCOPUS:0035035756

VL - 51

SP - 315

EP - 324

JO - Arzneimittel-Forschung/Drug Research

JF - Arzneimittel-Forschung/Drug Research

SN - 0004-4172

IS - 4

ER -